Breast Cancer

anatomy_BC
PSK has also been shown to be effective in adjuvant therapy for breast cancer (Table 2). The trials showed a trend towards an improvement in patients treated with chemotherapy plus PSK than those treated with chemotherapy alone although the differences were short of significance23, 24. Overall disease survival was also better in the chemotherapy plus PSK but also did not reach significance. However, when the patients were stratified according to HLA-B40 antigen, the results showed that those positive for HLA-B40 had a better survival rate at 10 years than those who were HLA-B40 negative (Fig. 4)(100% (9/9) versus 55% (7/13), p <0.05).25 It was concluded that HLA-B40 positive patients may benefit greatly from adjuvant immunotherapy with PSK.

RefsPatientsStageTreatmentOutcome
23914 cases
Standard or
Radical
mastectomy
IIA, IIB,
III
1.Patients(ER+tumours)
chemo +/- tamoxifen
2.Patients (ER- tumour)
Chemo +/- PSK
Longer overall survival for
patients in Stage IIA T2N1 cancer ER- and node-negative treated with chemo + PSK compared with other ER- subgroups without PSK.
24227 cases
operable breast
cancer with v+
and/or n+
involvement
Chemo (n=77)
Chemo +LMS (n=76)
Chemo +, PSK (n=74)
Risk ratio lower in the chemo+ PSK group. Overall and disease- free survival rates not significant
for all groups.
**See later published analysis of the HLA-status of these patients below (ref 25)
25134 cases
Typed as HLA-
A, HLA-B and
HLA-C
Operable
with v+
and/or nv+
Previously randomised
into two groups(ref 23):
1. Chemo
2. Chemo +PSK
Each group stratified by
HLA type B40+ or
B40-.
Disease-free survival at 5 and 10 Years for chemo + PSK group:
HLA-B40+ : 100%;
HLA-B40- : 76% and 55%, respectively.
Significant difference at p =0.05.

fig 4

BreastCancer

BreastCancerII